Syncom Formulations (India) Limited (NSE:SYNCOMF) — Stock Price
Syncom Formulations (India) Limited (NSE:SYNCOMF) is currently trading at Rs14.34 INR, up 6.62% today. Over the past 52 weeks, shares have ranged between Rs10.30 and Rs18.08. This page tracks Syncom Formulations (India) Limited's live share price on the NSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Syncom Formulations (India) Limited market capitalisation.
Syncom Formulations (India) Limited (SYNCOMF) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Syncom Formulations (India) Limited's daily closing share price and trading volume on the NSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Syncom Formulations (India) Limited Income Statement — Revenue, Profit & Earnings by Year
Syncom Formulations (India) Limited's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Rs4.65 Billion | Rs2.63 Billion | Rs2.24 Billion | Rs2.18 Billion | Rs2.39 Billion |
| Cost of Revenue | Rs3.07 Billion | Rs1.57 Billion | Rs1.42 Billion | Rs1.47 Billion | Rs1.67 Billion |
| Gross Profit | Rs1.58 Billion | Rs559.50 Million | Rs825.58 Million | Rs709.74 Million | Rs722.43 Million |
| Research & Development | — | — | — | — | — |
| SG&A | Rs535.34 Million | Rs22.01 Million | Rs26.24 Million | Rs18.86 Million | Rs14.17 Million |
| Total Operating Expenses | Rs513.72 Million | Rs815.82 Million | Rs674.68 Million | Rs315.47 Million | Rs373.24 Million |
| Operating Income | Rs489.38 Million | Rs213.87 Million | Rs152.19 Million | Rs147.48 Million | Rs287.20 Million |
| EBITDA | Rs711.74 Million | Rs430.28 Million | Rs341.47 Million | Rs319.59 Million | Rs450.31 Million |
| EBIT | Rs663.72 Million | Rs383.05 Million | Rs296.08 Million | Rs280.11 Million | Rs409.96 Million |
| Interest Expense | Rs8.65 Million | Rs43.52 Million | Rs30.35 Million | Rs18.28 Million | Rs2.92 Million |
| Income Before Tax | Rs655.13 Million | Rs339.53 Million | Rs265.73 Million | Rs261.76 Million | Rs407.04 Million |
| Income Tax Expense | Rs160.78 Million | Rs86.39 Million | Rs65.02 Million | Rs63.85 Million | Rs115.32 Million |
| Net Income | Rs494.35 Million | Rs253.14 Million | Rs200.71 Million | Rs197.90 Million | Rs291.72 Million |
Syncom Formulations (India) Limited Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Syncom Formulations (India) Limited's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Rs4.13 Billion | Rs4.05 Billion | Rs3.78 Billion | Rs3.08 Billion | Rs2.92 Billion |
| Total Current Assets | Rs2.70 Billion | Rs2.75 Billion | Rs1.82 Billion | Rs1.40 Billion | Rs1.90 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | Rs892.16 Million | Rs681.82 Million | Rs700.17 Million | Rs400.31 Million | Rs713.42 Million |
| Net Receivables | Rs1.29 Billion | Rs1.14 Billion | Rs824.00 Million | Rs715.27 Million | Rs867.59 Million |
| Inventory | Rs413.32 Million | Rs210.81 Million | Rs212.00 Million | Rs195.06 Million | Rs225.55 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | Rs0.00 | Rs0.00 |
| Total Liabilities | Rs711.23 Million | Rs1.17 Billion | Rs1.22 Billion | Rs860.17 Million | Rs1.04 Billion |
| Total Current Liabilities | Rs593.11 Million | Rs1.07 Billion | Rs1.13 Billion | Rs782.56 Million | Rs967.04 Million |
| Long-term Debt | — | — | — | Rs0.00 | Rs0.00 |
| Net Debt | Rs38.72 Million | Rs91.93 Million | Rs823.02 Million | Rs575.75 Million | Rs594.47 Million |
| Total Stockholder Equity | Rs3.42 Billion | Rs2.88 Billion | Rs2.56 Billion | Rs2.22 Billion | Rs1.88 Billion |
| Retained Earnings | Rs1.54 Billion | Rs1.05 Billion | Rs793.63 Million | Rs621.12 Million | Rs423.22 Million |
Syncom Formulations (India) Limited Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Syncom Formulations (India) Limited generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Rs234.36 Million | Rs-59.58 Million | Rs105.29 Million | Rs163.29 Million | Rs-19.93 Million |
| Capital Expenditures | Rs99.59 Million | Rs81.36 Million | Rs206.35 Million | Rs113.13 Million | Rs27.25 Million |
| Free Cash Flow | Rs134.77 Million | Rs-140.95 Million | Rs-101.05 Million | Rs50.16 Million | Rs-47.19 Million |
| Investing Cash Flow | Rs-182.04 Million | Rs830.20 Million | Rs-449.53 Million | Rs-270.73 Million | Rs-754.62 Million |
| Financing Cash Flow | Rs-679.03 Million | Rs-145.58 Million | Rs350.01 Million | Rs82.94 Million | Rs719.60 Million |
| Dividends Paid | — | — | Rs28.20 Million | Rs28.20 Million | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | Rs51.94 Million | Rs47.22 Million | Rs45.39 Million | Rs39.48 Million | Rs40.35 Million |
| Change in Cash | Rs-626.71 Million | Rs625.04 Million | Rs5.78 Million | Rs-24.50 Million | Rs-54.56 Million |
Syncom Formulations (India) Limited Earnings History — EPS Actual vs. Analyst Estimates
Track Syncom Formulations (India) Limited's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 18, 2026 | — | — | — |
| Feb 09, 2026 | — | — | — |
| Nov 10, 2025 | — | — | — |
| Aug 11, 2025 | — | — | — |
| May 15, 2025 | — | — | — |
| Feb 12, 2025 | — | — | — |
| Nov 06, 2024 | — | — | — |